Identifying predictive markers of efficacy in antiepidermal growth factor receptor therapies in metastatic colorectal cancer
- VernacularTitle:抗表皮生长因子受体单抗治疗晚期结直肠癌疗效预测因子的研究
- Author:
Rongbo LIN
;
Nanfeng FAN
;
Xiaojie WANG
;
Yunbin YE
;
Ling CHEN
;
Jie LIU
- Publication Type:Journal Article
- Keywords:
Antibodies,monoclonal;
Receptor,epidermal growth factor,Tretment outcome;
Forecasting
- From:
Cancer Research and Clinic
2008;20(9):644-646
- CountryChina
- Language:Chinese
-
Abstract:
The antiEGFR monoclonal antibodies cetuximab and panitumumab have been proven to be efficient in MCRC. The degree of EGFR expression (as confirmed by immunohistochemical analysis) did not correhte with the clinical response. In this review, we describe the current status of markers that might identify patients who are likely to benefit from treatment with cetuximab or panitumumab. These molecular markers include KRAS mutations, EGFR copy number, EGFR ligands (EGF, epiregulin), cyclin DI, IgG FcγR (FCGR2A-HI31R and FCGR3A-V158F), and nuclear factor-κB, that are crucial to avoid anti-EGFR treatment toxicity and reduce treatment cost.
